The Institute of Metabolic Disease (IMD), part of Baylor Scott & White Research Institute, develops analytical tests for clinical diagnosis, performs clinical testing and research testing and explores therapeutic approaches that encompass the complementary fields of metabolomics and metabolic disease, which are the focus of the Center of Metabolomics and the Center of Metabolic Translational Research, respectively. The two centers work in concert to research and address areas of unmet medical needs that span both rare and common diseases.
We offer specialized clinical diagnostic testing services accredited by the College of American Pathologist and CLIA, as well as mass spectrometric analytical and metabolomic expertise for research studies.
The Center of Metabolomics is focused on identifying novel biomarkers that will help to diagnose metabolic disorders, predict disease progression and improve treatment outcome of rare and more common diseases such as cancer, vascular disease and neurodegenerative disorders.
The Center of Metabolic Translational Research includes two areas of focus. Our first area of research is on lysosomal storage disorders. We have discovered novel mechanisms and patented novel biomarkers that can lead to treatments for Fabry disease. Our second area of focus is the exploration of the role of folate, one-carbon metabolism and methylation in major diseases, as well as the impact of treatment in vascular disease and neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.